By: Benzinga
UPDATE: Credit Suisse Raises PT to $68 on Eli Lilly on Patent Ruling Confidence
Credit Suisse maintained Eli Lilly (NYSE: LLY ) with an Outperform rating and raised the price target from $65.00 to $68.00. Credit Suisse noted, "We have raised our long-term forecasts for Alimta ex US revenues on higher confidence that the EU patent should hold until 2020 (from current assumption
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here